Clinical trials: Secukinumab
Healthy Male Subjects
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects
This is a Phase 1, Randomized, Double-blind, three-arm, Parallel group, Single-dose Study to Compare the Pharmacokinetics, Safety and immunogenicity of CT-P55, EU-approved Cosentyx and US-licensed Cosentyx in Healthy male Subjects
- Trial name
- NCT07054970
- Testing
- CT-P55, US-licensed Cosentyx, EU-approved Cosentyx
- Where
- 4 sites in Japan
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Celltrion
Psoriasis
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
This is a randomized, double-blinded, controlled Phase I study of CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of CMAB015 versus Cosentyx（Secukinumab…
- Trial name
- NCT05734482
- Testing
- Secukinumab
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO
This Observational protocol will attempt to verify two recent and very critical concepts in ALZ Clinical Research by studying high-risk individuals who already are taking medications which may prevent the onset of ALZ.
- Trial name
- PCD=OOALZ (NCT02835716)
- Testing
- roflumilast, ustekinumab
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Millennium Magnetic Technologies, LLC
Tendinopathy
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
The purpose of this study was to investigate the efficacy and safety of secukinumab subcutaneously (s.c.) compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy and failure to conventional therapy.
- Trial name
- UnchAIN (NCT05569174)
- Testing
- Secukinumab
- Where
- 19 sites in Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
This is a randomized, double-blinded, controlled Phase I study of new process CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of new process CMAB015…
- Trial name
- NCT07254325
- Testing
- Secukinumab 150mg s.c.
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriasis
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
This is a randomized, open-label, controlled Phase I study of BR201 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of BR201 versus Cosentyx（Secukinumab ） in…
- Trial name
- NCT06126718
- Testing
- BR201, Cosentyx（Secukinumab ）
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2306 Injection vs Cosentyx® (EU-licensed and US-licensed) in healthy Chinese…
- Trial name
- NCT04711343
- Testing
- BAT2306, Cosentyx (US-licensed), Cosentyx (EU-licensed)
- Where
- China
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions